Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.

Rong Z, Martel G, Vandenbroucke-Menu F, Adam R, Lapointe R.

HPB (Oxford). 2014 Apr;16(4):342-9. doi: 10.1111/hpb.12138.

2.

[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].

Dede K, Láng I, Pörneczi B, Mester G, Fekete A, Kőszegi G, Mersich T, Besznyák I, Bursics A.

Magy Seb. 2013 Dec;66(6):325-30. doi: 10.1556/MaSeb.66.2013.6.4. Hungarian.

PMID:
24333977
3.

Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.

Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.

Eur J Surg Oncol. 2015 Jul;41(7):868-74. doi: 10.1016/j.ejso.2015.03.223. Epub 2015 Mar 24.

PMID:
25865557
4.

Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.

Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P.

HPB (Oxford). 2010 Feb;12(1):37-42. doi: 10.1111/j.1477-2574.2009.00119.x.

5.

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.

Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R.

BMC Cancer. 2014 May 7;14:323. doi: 10.1186/1471-2407-14-323.

6.

Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.

Dede K, Mersich T, Besznyák I, Zaránd A, Salamon F, Baranyai ZS, Landherr L, Jakab F, Bursics A.

Pathol Oncol Res. 2013 Jul;19(3):501-8. doi: 10.1007/s12253-013-9608-2. Epub 2013 Feb 19.

PMID:
23420304
7.

Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.

Viganò L, Capussotti L, Barroso E, Nuzzo G, Laurent C, Ijzermans JN, Gigot JF, Figueras J, Gruenberger T, Mirza DF, Elias D, Poston G, Letoublon C, Isoniemi H, Herrera J, Sousa FC, Pardo F, Lucidi V, Popescu I, Adam R.

Ann Surg Oncol. 2012 Sep;19(9):2786-96. doi: 10.1245/s10434-012-2382-7. Epub 2012 May 24.

PMID:
22622469
8.

Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.

Lubezky N, Winograd E, Papoulas M, Lahat G, Shacham-Shmueli E, Geva R, Nakache R, Klausner J, Ben-Haim M.

J Gastrointest Surg. 2013 Mar;17(3):527-32. doi: 10.1007/s11605-012-2108-y. Epub 2013 Jan 9.

PMID:
23299220
9.

Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.

Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ueno M, Yamaguchi T.

Asia Pac J Clin Oncol. 2014 Dec;10(4):322-9. doi: 10.1111/ajco.12094. Epub 2013 Aug 5.

PMID:
23915091
10.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

PMID:
26338525
11.

Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.

Scoggins CR, Campbell ML, Landry CS, Slomiany BA, Woodall CE, McMasters KM, Martin RC.

Ann Surg Oncol. 2009 Jan;16(1):35-41. doi: 10.1245/s10434-008-0190-x. Epub 2008 Nov 6.

PMID:
18987915
12.

Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.

Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lechi Y, Tianshu L, Jia F, Xinyu Q, Jianmin X.

Ann Surg Oncol. 2012 Sep;19(9):2860-8. doi: 10.1245/s10434-012-2356-9. Epub 2012 Apr 12.

PMID:
22526903
13.

Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.

Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.

Jpn J Clin Oncol. 2011 Apr;41(4):490-7. doi: 10.1093/jjco/hyr008. Epub 2011 Feb 7.

PMID:
21303790
14.

Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.

Faron M, Chirica M, Tranchard H, Balladur P, de Gramont A, Afchain P, Andre T, Paye F.

J Gastrointest Cancer. 2014 Sep;45(3):298-306. doi: 10.1007/s12029-014-9594-y.

PMID:
24610400
15.

Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.

Tsutsumi S, Fujii T, Yamaguchi S, Suto T, Yajima R, Morita H, Kato T, Asao T, Kuwano H.

Hepatogastroenterology. 2014 May;61(131):633-7.

PMID:
26176048
16.

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.

Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24225157
17.

Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.

Siperstein AE, Berber E, Ballem N, Parikh RT.

Ann Surg. 2007 Oct;246(4):559-65; discussion 565-7.

PMID:
17893492
18.

Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.

DʼAngelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N.

Ann Surg. 2015 Feb;261(2):353-60. doi: 10.1097/SLA.0000000000000614.

19.

Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.

Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB.

Oncology. 2013;85(5):283-9. doi: 10.1159/000355475. Epub 2013 Nov 6.

PMID:
24217184
20.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

Supplemental Content

Support Center